Structures by: Arion V. B.
Total: 308
C61H67Mn6N7O24Si2,1.2(H2O),C7H7NO2
C61H67Mn6N7O24Si2,1.2(H2O),C7H7NO2
Macromolecules (2016) 49, 17 6163
a=19.029(5)Å b=25.005(5)Å c=19.750Å
α=90° β=105.62° γ=90°
C13H19N5OS
C13H19N5OS
Journal of medicinal chemistry (2019) 62, 2 512-530
a=22.7776(4)Å b=6.85850(10)Å c=9.8800(2)Å
α=90° β=98.889(2)° γ=90°
C18H20ClCuN5OS,CH4O
C18H20ClCuN5OS,CH4O
Journal of medicinal chemistry (2019) 62, 2 512-530
a=16.5043(12)Å b=17.7857(12)Å c=7.1311(6)Å
α=90° β=96.241(3)° γ=90°
C14H21N5OS
C14H21N5OS
Journal of medicinal chemistry (2019) 62, 2 512-530
a=6.1236(4)Å b=7.9500(6)Å c=30.956(2)Å
α=90° β=92.419(4)° γ=90°
3(C16H22ClCuN5OS),0.75(CH4O)
3(C16H22ClCuN5OS),0.75(CH4O)
Journal of medicinal chemistry (2019) 62, 2 512-530
a=24.702(4)Å b=9.1959(14)Å c=25.064(5)Å
α=90° β=100.971(6)° γ=90°
C12H17N5OS
C12H17N5OS
Journal of medicinal chemistry (2019) 62, 2 512-530
a=11.544(3)Å b=13.204(3)Å c=10.086(3)Å
α=90° β=112.081(7)° γ=90°
C18H21N5OS
C18H21N5OS
Journal of medicinal chemistry (2019) 62, 2 512-530
a=7.1287(2)Å b=15.0536(6)Å c=16.4704(6)Å
α=90° β=97.810(2)° γ=90°
C16H23N5O2S
C16H23N5O2S
Journal of medicinal chemistry (2019) 62, 2 512-530
a=13.3622(18)Å b=5.8899(6)Å c=21.414(3)Å
α=90° β=91.631(5)° γ=90°
C13H18ClCuN5OS
C13H18ClCuN5OS
Journal of medicinal chemistry (2019) 62, 2 512-530
a=15.7566(11)Å b=14.2967(9)Å c=14.2703(10)Å
α=90° β=92.971(3)° γ=90°
(C12H18ClCuN5O2S),2(H2O)
(C12H18ClCuN5O2S),2(H2O)
Journal of medicinal chemistry (2019) 62, 2 512-530
a=9.2626(8)Å b=9.5087(8)Å c=11.0617(9)Å
α=89.565(2)° β=76.519(2)° γ=67.742(2)°
C12H16ClCuN5OS,C3H7NO
C12H16ClCuN5OS,C3H7NO
Journal of medicinal chemistry (2019) 62, 2 512-530
a=9.3959(3)Å b=19.8889(6)Å c=10.9744(3)Å
α=90° β=108.3661(7)° γ=90°
[Chlorido(hapto^6^-p-cymene)(N-{4-hydroxyphenyl}-2-pyridinecarbothioamide)osmium(II)] chloride
c22H24ClN2OOsS,Cl
Chemical Science (2013) 4, 4 1837
a=14.4797(14)Å b=11.9305(11)Å c=13.1126(13)Å
α=90.00° β=98.591(3)° γ=90.00°
[Chlorido(hapto^6^-p-cymene)(N-{4-fluorophenyl}-2-pyridinecarbothioamide)ruthenium(II)] chloride
C22H23ClFN2RuS,C3H6O,Cl
Chemical Science (2013) 4, 4 1837
a=14.0346(9)Å b=8.6278(5)Å c=22.7026(13)Å
α=90.00° β=90.353(3)° γ=90.00°
N-(2-Methyl-5,11-dihydroindolo[3,2-c]quinolin-6-ylidene)-N'-(1-pyridin-2- yl-ethylidene)azine methanol solvate
C23H19N5,CH4O
Inorganica Chimica Acta (2012) 393, 252-260
a=11.4565(7)Å b=13.1693(7)Å c=13.3620(8)Å
α=90.00° β=95.346(3)° γ=90.00°
N-(2-Chloro-5,11-dihydroindolo[3,2-c]quinolin-6-ylidene)-N'-(1-pyridin-2-yl -ethylidene)azine diethanol solvate
C22H16ClN5,2(C2H6O)
Inorganica Chimica Acta (2012) 393, 252-260
a=7.4390(6)Å b=15.6393(14)Å c=21.2178(18)Å
α=90.00° β=99.794(5)° γ=90.00°
{(hapto^6^-p-Cymene)[N-(8-bromo-5,11-dihydroindolo[3,2-c]quinolin-6- ylidene)-kappaN'-(1-kappaN-pyridin-2-yl-ethylidene)]azine chloridoruthenium(II)}chloride monomethanol solvate
C32H30BrClN5Ru,CH4O,Cl
Inorganica Chimica Acta (2012) 393, 252-260
a=9.3254(5)Å b=13.5216(8)Å c=13.5306(8)Å
α=67.646(4)° β=89.989(4)° γ=85.886(3)°
N-(8-Methyl-5,11-dihydroindolo[3,2-c]quinolin-6-ylidene)-N'- (1-pyridin-2-yl-ethylidene)azine
C23H19N5
Inorganica Chimica Acta (2012) 393, 252-260
a=17.0279(16)Å b=11.1855(11)Å c=12.0305(11)Å
α=90.00° β=129.439(4)° γ=90.00°
{(hapto^6^-p-Cymene)[N-(8-methyl-5,11-dihydroindolo[3,2-c]quinolin-6- ylidene)-kappaN'-(1-kappaN-pyridin-2-yl-ethylidene)]azine chloridoosmium(II)}chloride hydrate diethyl ether solvate
C33H33ClN5Os,Cl,1.38(H2O),0.25(C4H10O)
Inorganica Chimica Acta (2012) 393, 252-260
a=11.2980(9)Å b=14.4940(12)Å c=21.3506(18)Å
α=99.901(5)° β=92.072(4)° γ=98.838(5)°
{(hapto^6^-p-Cymene)[N-(8-bromo-5,11-dihydroindolo[3,2-c]quinolin-6- ylidene)-kappaN'-(1-kappaN-pyridin-2-yl-ethylidene)]azine chloridoosmium(II)}chloride hydrate
C32H30BrClN5Os,Cl,0.75(H2O)
Inorganica Chimica Acta (2012) 393, 252-260
a=12.3508(4)Å b=13.3564(5)Å c=20.5840(8)Å
α=98.018(2)° β=95.312(2)° γ=112.859(3)°
(2R,3aR,5aR,7aS,10aS,10bS,10cR)-2-methoxy-2,3,3a,7a,8, 10a,10b,10c-octahydro-5aH-1,9-dioxa- dicyclopenta[a,h]naphthalen-10-one
C15H18O4
Organic letters (2006) 8, 17 3849-3851
a=6.3696(2)Å b=7.2069(2)Å c=29.1029(10)Å
α=90.00° β=90.00° γ=90.00°
3-Aminopyridine-2-carbaldehyde thiosemicarbazone
C7H9N5S
Journal of medicinal chemistry (2009) 52, 16 5032-5043
a=18.5732(8)Å b=5.5273(2)Å c=17.2799(7)Å
α=90.00° β=90.00° γ=90.00°
Pyridine-2-carbaldehyde N,N-dimethylthiosemicarbazone
C9H12N4S
Journal of medicinal chemistry (2009) 52, 16 5032-5043
a=7.3747(2)Å b=7.4532(2)Å c=9.6324(3)Å
α=97.192(2)° β=109.630(2)° γ=95.020(2)°
C14H16GaN10S2,C2H6O,NO3
C14H16GaN10S2,C2H6O,NO3
Journal of medicinal chemistry (2009) 52, 16 5032-5043
a=9.3441(7)Å b=9.7491(10)Å c=12.9501(13)Å
α=102.437(6)° β=95.239(5)° γ=96.569(5)°
[Bis(3-aminopyridine-2-carbaldehyde thiosemicarbazonato)- N,N,S-iron(III)] nitrate hydrate
2(C14H16FeN10S2),NO6,NO3,4(H2O)
Journal of medicinal chemistry (2009) 52, 16 5032-5043
a=9.2033(4)Å b=23.0998(11)Å c=21.2104(8)Å
α=90.00° β=92.473(3)° γ=90.00°
Trans-[Dichlorotetraindazoleruthenium(III)]chloride methanol disolvate
C30H32Cl3N8O2Ru
Journal of medicinal chemistry (2005) 48, 8 2831-2837
a=17.681(4)Å b=11.082(2)Å c=16.738(3)Å
α=90.00° β=102.46(3)° γ=90.00°
Trans-[Dichlorotetraindazoleruthenium(II)]acetone disolvate
C34H36Cl2N8O2Ru
Journal of medicinal chemistry (2005) 48, 8 2831-2837
a=10.891(2)Å b=13.279(3)Å c=14.399(3)Å
α=65.66(3)° β=69.04(3)° γ=68.36(3)°
3-(2-trans-Cyanoethenyl)-5'-fluoro-spiro[2-H-azirine-2,2'- tricyclo[3.3.1.1^3',7'^]decane
C14H15FN2
Organic letters (2010) 12, 10 2366-2369
a=6.4202(3)Å b=27.8217(11)Å c=6.4690(2)Å
α=90.00° β=97.081(2)° γ=90.00°
4-Azi-1-fluoroadamantane
C10H13FN2
Organic letters (2010) 12, 10 2366-2369
a=14.0215(4)Å b=14.0215(4)Å c=8.8612(3)Å
α=90.00° β=90.00° γ=90.00°
C-Hexyl-6,10:12,16:18,22:24,4-O,O'-tetrakis(quinoxaline- 2,3-diyl)calix[4]resorcinarene phenyl azide adduct
C84H80N8O8,C6H5N3
Organic letters (2009) 11, 14 3056-3058
a=13.5021(9)Å b=15.7541(8)Å c=18.9376(11)Å
α=70.524(2)° β=88.842(3)° γ=77.787(3)°
(OC-6-33)-Diamminebis(3-carboxypropanoato)dichloroplatinum(IV) diethyl ether solvate
C12H26Cl2N2O9Pt
Journal of medicinal chemistry (2007) 50, 26 6692-6699
a=23.5231(10)Å b=10.6395(4)Å c=8.1822(3)Å
α=90.00° β=90.00° γ=90.00°
9-Nitro-6-(alpha-picolylamino)-7,12-dihydroindolo[3,2-d][1]benzazepine
C22H17N5O2
Journal of medicinal chemistry (2007) 50, 25 6343-6355
a=10.8951(10)Å b=20.050(2)Å c=8.6412(9)Å
α=90.00° β=90.160(4)° γ=90.00°
(hapto^6^-p-Cymene)[9-pyridin-kappaN-2-yl-(E)-methylidene)amino-kappaN-7,12- dihydroindolo[3,2-d][1]benzazepin-6(5H)-one]chloroosmium(II) chloride acetone solvate
C35H36Cl2N4O2Os
Journal of medicinal chemistry (2007) 50, 25 6343-6355
a=9.876(2)Å b=9.6263(19)Å c=17.460(4)Å
α=90.00° β=104.32(3)° γ=90.00°
(hapto^6^-p-Cymene)[9-pyridin-kappaN-2-yl-(E)-methylidene)amino-kappaN-7,12- dihydroindolo[3,2-d][1]benzazepin-6(5H)-one]chlororuthenium(II) chloride acetone solvate
C35H36Cl2N4O2Ru
Journal of medicinal chemistry (2007) 50, 25 6343-6355
a=9.872(2)Å b=9.6208(19)Å c=17.434(4)Å
α=90.00° β=104.05(3)° γ=90.00°
(hapto^6^-p-Cymene){9-nitro-6-[(alpha-picolyl-kappaN)imino-kappaN]-7,12- dihydroindolo[3,2-d][1]benzazepine}chlororuthenium(II) chloride diethanol solvate
C36H43Cl2N5O4Ru
Journal of medicinal chemistry (2007) 50, 25 6343-6355
a=12.2485(4)Å b=12.6418(5)Å c=14.3132(5)Å
α=95.421(2)° β=108.122(2)° γ=118.054(2)°
(hapto^6^-p-Cymene){9-nitro-6-[(alpha-picolyl-kappaN)imino-kappaN]-7,12- dihydroindolo[3,2-d][1]benzazepine}chlororuthenium(II) chloride diethanol water solvate
C36H45Cl2N5O5Ru
Journal of medicinal chemistry (2007) 50, 25 6343-6355
a=10.771(2)Å b=25.040(5)Å c=13.238(3)Å
α=90.00° β=91.84(3)° γ=90.00°
(hapto^6^-p-Cymene){9-bromo-6-[(alpha-picolyl-kappaN)imino-kappaN]-7,12- dihydroindolo[3,2-d][1]benzazepine}chloroosmium(II) chloride ethanol water solvate
C130H133Br4Cl8N16O3.5Os4
Journal of medicinal chemistry (2007) 50, 25 6343-6355
a=13.8319(5)Å b=14.1376(5)Å c=18.3912(6)Å
α=98.511(2)° β=107.338(2)° γ=102.012(2)°
(hapto^6^-p-Cymene){9-nitro-6-[(alpha-picolyl-kappaN)imino-kappaN]-7,12- dihydroindolo[3,2-d][1]benzazepine}chloroosmium(II) chloride ethanol water solvate
C35.9H42.95Cl2N5O4.08Os
Journal of medicinal chemistry (2007) 50, 25 6343-6355
a=12.2836(4)Å b=12.6756(4)Å c=14.2592(6)Å
α=95.491(2)° β=107.998(2)° γ=118.072(2)°
(hapto^6^-p-Cymene){6-[(alpha-picolyl-kappaN)imino-kappaN]-7,12- dihydroindolo[3,2-d][1]benzazepine}chloroosmium(II) chloride water solvate
C32H32.5Cl2N4O0.25Os
Journal of medicinal chemistry (2007) 50, 25 6343-6355
a=13.9580(7)Å b=14.0949(7)Å c=18.3531(9)Å
α=96.749(3)° β=108.022(3)° γ=102.050(3)°
4,4-dibromotetracyclo[6.2.1.0^2,7^.0^3,5^]undec-9-ene
C11H12Br2
Organic letters (2007) 9, 1 113-115
a=9.6375(8)Å b=10.0279(8)Å c=11.1469(9)Å
α=90.00° β=109.864(4)° γ=90.00°
4,5exo-dibromo-endo-tricyclo[6.2.1.0^2,7^]undeca-3,9-diene
C11H12Br2
Organic letters (2007) 9, 1 113-115
a=13.0891(12)Å b=10.9312(9)Å c=14.5270(13)Å
α=90.00° β=90.00° γ=90.00°
Rac-(1R,2S,6R,7R,10R)-1,10-dibromotricyclo[5.2.2.0^2,6^]undeca-4,8-diene
C11H12Br2
Organic letters (2007) 9, 1 113-115
a=6.29660(10)Å b=12.3168(3)Å c=26.7947(7)Å
α=90.00° β=90.00° γ=90.00°
Rac-(1R,2S,6R,7R,10R)-1,10-dibromotricyclo[5.2.2.0^2,6^]undeca-3,8-diene
C11H12Br2
Organic letters (2007) 9, 1 113-115
a=12.886(3)Å b=11.131(2)Å c=7.1850(10)Å
α=90.00° β=90.00° γ=90.00°
C45H39N7
C45H39N7
Dalton transactions (Cambridge, England : 2003) (2020) 49, 4 1143-1156
a=15.9799(10)Å b=15.9799(10)Å c=15.7925(9)Å
α=90° β=90° γ=120°
C48H36F9N7
C48H36F9N7
Dalton transactions (Cambridge, England : 2003) (2020) 49, 4 1143-1156
a=12.9590(8)Å b=13.5286(10)Å c=14.2464(10)Å
α=70.930(2)° β=64.023(2)° γ=81.799(2)°
C23H18BrN5
C23H18BrN5
Dalton transactions (Cambridge, England : 2003) (2019) 48, 28 10464-10478
a=18.405(4)Å b=8.2958(16)Å c=13.230(3)Å
α=90° β=103.962(8)° γ=90°
C22H16BrCl2CuN5,0.55(CH4O)
C22H16BrCl2CuN5,0.55(CH4O)
Dalton transactions (Cambridge, England : 2003) (2019) 48, 28 10464-10478
a=37.232(3)Å b=11.3330(11)Å c=11.6674(10)Å
α=90° β=107.494(3)° γ=90°
C23H19Cl2CuN5,1.2(C3H7NO),0.25(H2O)
C23H19Cl2CuN5,1.2(C3H7NO),0.25(H2O)
Dalton transactions (Cambridge, England : 2003) (2019) 48, 28 10464-10478
a=9.7602(13)Å b=13.4027(15)Å c=20.685(2)Å
α=98.235(4)° β=92.013(5)° γ=93.367(4)°
C23H18BrCl2CuN5,2(C3H7NO)
C23H18BrCl2CuN5,2(C3H7NO)
Dalton transactions (Cambridge, England : 2003) (2019) 48, 28 10464-10478
a=12.0530(9)Å b=16.7234(14)Å c=17.8152(15)Å
α=105.698(3)° β=105.962(3)° γ=106.665(3)°
C66H51Cl4Cu3N15,1.25(H2O),2(C3H7NO),2(Cl)
C66H51Cl4Cu3N15,1.25(H2O),2(C3H7NO),2(Cl)
Dalton transactions (Cambridge, England : 2003) (2019) 48, 28 10464-10478
a=13.0443(3)Å b=14.9957(3)Å c=20.2999(4)Å
α=92.0747(8)° β=103.4914(8)° γ=112.4054(8)°
C24H16ClCuN5O3Se,7[H2O]
C24H16ClCuN5O3Se,7[H2O]
New Journal of Chemistry (2020) 44, 30 13195-13206
a=7.5617(2)Å b=15.7974(3)Å c=22.4261(7)Å
α=90° β=91.725(3)° γ=90°
C36H24N8NiO6Se2,7[H2O]
C36H24N8NiO6Se2,7[H2O]
New Journal of Chemistry (2020) 44, 30 13195-13206
a=7.35306(19)Å b=23.6850(5)Å c=22.9755(8)Å
α=90° β=93.681(3)° γ=90°
2,3-{(R,S)-(ferrocene-1,1'-dicarbonyl)}-O-methyl-alpha-D-glucopyranoside
C19H20FeO8.H2O
New Journal of Chemistry (2002) 26, 6 671
a=5.8080(10)Å b=10.750(2)Å c=14.772(3)Å
α=90.00° β=93.44(3)° γ=90.00°
C9H14Cl2CuN5O3S,H2O,C2HCl2O2
C9H14Cl2CuN5O3S,H2O,C2HCl2O2
New Journal of Chemistry (2019) 43, 3 1340
a=7.5477(3)Å b=17.3408(6)Å c=15.7754(6)Å
α=90° β=95.6740(10)° γ=90°
C8H10Cl2CuN5O2S,C2HCl2O2
C8H10Cl2CuN5O2S,C2HCl2O2
New Journal of Chemistry (2019) 43, 3 1340
a=13.8439(9)Å b=11.9326(9)Å c=11.6222(7)Å
α=90.00° β=110.322(3)° γ=90.00°
C16H20Cl2CuN5O3S,C2HCl2O2
C16H20Cl2CuN5O3S,C2HCl2O2
New Journal of Chemistry (2019) 43, 3 1340
a=9.5794(11)Å b=17.6082(16)Å c=15.4996(15)Å
α=90° β=105.502(4)° γ=90°
C14H16Cl2CuN5O3S,C2H6O,C2HCl2O2
C14H16Cl2CuN5O3S,C2H6O,C2HCl2O2
New Journal of Chemistry (2019) 43, 3 1340
a=9.4329(4)Å b=20.2920(8)Å c=14.1277(5)Å
α=90.00° β=99.180(2)° γ=90.00°
C9H12Cl2CuN5O2S,C2HCl2O2,C2H6O
C9H12Cl2CuN5O2S,C2HCl2O2,C2H6O
New Journal of Chemistry (2019) 43, 3 1340
a=8.9820(6)Å b=9.8523(6)Å c=13.4982(9)Å
α=103.683(3)° β=94.647(3)° γ=110.613(3)°
C8H10Cl2CuN5O2S,C2HCl2O2
C8H10Cl2CuN5O2S,C2HCl2O2
New Journal of Chemistry (2019) 43, 3 1340
a=10.0981(7)Å b=21.8935(15)Å c=17.1161(12)Å
α=90.00° β=106.756(3)° γ=90.00°
C20H22N8Pd
C20H22N8Pd
New Journal of Chemistry (2019) 43, 27 10973
a=5.4343(3)Å b=8.4913(3)Å c=10.9739(5)Å
α=88.134(3)° β=80.550(4)° γ=76.336(4)°
C18H18N8Pd
C18H18N8Pd
New Journal of Chemistry (2019) 43, 27 10973
a=4.5732(7)Å b=9.8193(12)Å c=10.5527(13)Å
α=71.200(11)° β=86.444(11)° γ=76.934(12)°
C20H22N8Pd
C20H22N8Pd
New Journal of Chemistry (2019) 43, 27 10973
a=4.4346(9)Å b=10.181(4)Å c=21.341(7)Å
α=90° β=92.15(2)° γ=90°
3(C22H26N8Pd),2(CHCl3),H4O2
3(C22H26N8Pd),2(CHCl3),H4O2
New Journal of Chemistry (2019) 43, 27 10973
a=30.046(8)Å b=6.8662(12)Å c=23.785(6)Å
α=90° β=126.80(4)° γ=90°
Bis(diammine)(hapto$6!-p-cymene)chlorido-ruthenium(ii) hexafluorophosphate
C10H20ClN2Ru,F6P
Dalton Transactions (2009) 17 3334-3339
a=8.0544(2)Å b=8.8166(2)Å c=11.2876(3)Å
α=87.861(2)° β=88.256(2)° γ=78.272(2)°
Tris(mu!2$-methoxido)-bis(hapto$6!-p-cymene)-di-osmium(ii) hexafluorophosphate
C23H37O3Os2,F6P
Dalton Transactions (2009) 17 3334-3339
a=11.2483(3)Å b=13.6694(4)Å c=34.2630(9)Å
α=90.00° β=90.00° γ=90.00°
Bis(2,3,5,6,8,9-hexahydro-1,4,7,10-benzotetraoxacyclododecin- 12-aminium) hexafluorosilicate dihydrate
2(C12H18NO4),F6Si,2(H2O)
Dalton transactions (Cambridge, England : 2003) (2007) 27 2915-2924
a=21.8548(6)Å b=8.0635(2)Å c=8.5300(2)Å
α=90.00° β=98.599(2)° γ=90.00°
Bis(1,4,7-trioxa-10-azoniacyclododecane) bis(aquapentafluorosilicate) trihydrate
2(C8H18NO3),2(F5H2O1Si1),2(H2O1),O1
Dalton transactions (Cambridge, England : 2003) (2007) 27 2915-2924
a=14.8889(7)Å b=9.3635(5)Å c=20.3291(9)Å
α=90.00° β=93.900(3)° γ=90.00°
Cis,cis,cis- dichlorobis(dimethylsulfoxide)bis(indazole)ruthenium(ii)
C18H24Cl2N4O2RuS2
Dalton transactions (Cambridge, England : 2003) (2005) 14 2355-2364
a=12.194(2)Å b=12.888(3)Å c=14.720(3)Å
α=90.00° β=107.68(3)° γ=90.00°
Trans,cis,cis- dichlorobis(dimethylsulfoxide)bis(indazole)ruthenium(ii)
C18H24Cl2N4O2RuS2
Dalton transactions (Cambridge, England : 2003) (2005) 14 2355-2364
a=11.833(2)Å b=13.477(3)Å c=16.340(3)Å
α=113.96(3)° β=97.57(3)° γ=104.00(3)°
Trans,trans,trans- dichlorobis(dimethylsulfoxide)bis(indazole)ruthenium(ii)
C22H36Cl2N4O4RuS4
Dalton transactions (Cambridge, England : 2003) (2005) 14 2355-2364
a=27.0678(5)Å b=7.8991(5)Å c=14.0096(3)Å
α=90.00° β=94.1198(12)° γ=90.00°
Trans-dichlorobis(dimethylsulfoxide)amidineruthenium(ii) monohydrate
C13H23Cl2N3O3RuS2
Dalton transactions (Cambridge, England : 2003) (2005) 14 2355-2364
a=17.726(4)Å b=8.367(2)Å c=14.415(3)Å
α=90.00° β=113.56(3)° γ=90.00°
Trans- dichloro(dimethylsulfoxide)(indazole)amidineruthenium(ii) acetonitrile
C20H24Cl2N6ORuS
Dalton transactions (Cambridge, England : 2003) (2005) 14 2355-2364
a=12.235(2)Å b=14.800(3)Å c=13.614(3)Å
α=90.00° β=105.69(3)° γ=90.00°
C23H18ClCuN5,C3H7NO
C23H18ClCuN5,C3H7NO
Dalton transactions (Cambridge, England : 2003) (2019) 48, 28 10464-10478
a=10.3347(4)Å b=23.4454(7)Å c=11.0757(4)Å
α=90° β=117.7313(12)° γ=90°
C36H24CoN8O6Se2,7[H2O]
C36H24CoN8O6Se2,7[H2O]
New Journal of Chemistry (2020) 44, 30 13195-13206
a=7.18143(15)Å b=23.6904(7)Å c=22.8941(5)Å
α=90° β=94.7014(17)° γ=90°
C94H140Mn2N4O10Si4,5.5(H2O)
C94H140Mn2N4O10Si4,5.5(H2O)
Dalton transactions (Cambridge, England : 2003) (2019) 48, 18 5909-5922
a=15.790(2)Å b=14.221(2)Å c=23.958(3)Å
α=90.00° β=106.126(5)° γ=90.00°
C88H136Mn2N4O10Si4,4(CH2Cl2)
C88H136Mn2N4O10Si4,4(CH2Cl2)
Dalton transactions (Cambridge, England : 2003) (2019) 48, 18 5909-5922
a=11.8837(17)Å b=12.7755(19)Å c=18.564(3)Å
α=73.414(5)° β=81.359(5)° γ=72.378(5)°
C84H134Mn2N4O10Si4,6(CH2Cl2)
C84H134Mn2N4O10Si4,6(CH2Cl2)
Dalton transactions (Cambridge, England : 2003) (2019) 48, 18 5909-5922
a=13.7007(7)Å b=14.7166(7)Å c=15.9617(8)Å
α=67.7592(16)° β=66.1603(17)° γ=79.2085(17)°
C162H156Fe7N18O42S6Si12,3(ClO4),10(H2O)
C162H156Fe7N18O42S6Si12,3(ClO4),10(H2O)
Dalton transactions (Cambridge, England : 2003) (2017) 46, 6 1789-1793
a=41.2312(7)Å b=41.2312(7)Å c=41.2312(7)Å
α=90° β=90° γ=90°
C16H20Cu2N6O11S4
C16H20Cu2N6O11S4
Dalton transactions (Cambridge, England : 2003) (2017) 46, 12 3833-3847
a=13.5205(8)Å b=11.0919(6)Å c=16.2446(9)Å
α=90° β=96.219(5)° γ=90°
C12H19CuN3O6S4
C12H19CuN3O6S4
Dalton transactions (Cambridge, England : 2003) (2017) 46, 12 3833-3847
a=6.3750(3)Å b=12.3166(9)Å c=13.7976(12)Å
α=75.444(7)° β=77.550(6)° γ=76.945(5)°
C19H26ClN4O3PdS,Cl
C19H26ClN4O3PdS,Cl
Dalton transactions (Cambridge, England : 2003) (2016) 45, 34 13427-13439
a=6.9628(5)Å b=18.5602(13)Å c=17.4498(12)Å
α=90° β=101.011(2)° γ=90°
4(C19H26N4O3S),5(CH4O)
4(C19H26N4O3S),5(CH4O)
Dalton transactions (Cambridge, England : 2003) (2016) 45, 34 13427-13439
a=10.5018(4)Å b=24.7063(9)Å c=16.9193(7)Å
α=90° β=90.967(2)° γ=90°
C20H28Cl2CuN4O3S
C20H28Cl2CuN4O3S
Dalton transactions (Cambridge, England : 2003) (2016) 45, 34 13427-13439
a=20.3880(16)Å b=14.1122(7)Å c=15.9901(12)Å
α=90° β=100.503(6)° γ=90°
C19H26ClN4NiO3S,Cl
C19H26ClN4NiO3S,Cl
Dalton transactions (Cambridge, England : 2003) (2016) 45, 34 13427-13439
a=6.9292(2)Å b=18.4742(8)Å c=17.4103(7)Å
α=90° β=101.171(2)° γ=90°
1,1ï-bis(4,6-dimethyl-1,3-dioxane-2-yl)-ferrocene
C22H30FeO4
Dalton Transactions (2003) 15 3098
a=10.2611(2)Å b=10.3294(2)Å c=19.0505(4)Å
α=90.00° β=90.00° γ=90.00°
1,1ï-bis(4,6-dimethyl-1,3-dioxane-2-yl)-ferrocene
C22H30FeO4
Dalton Transactions (2003) 15 3098
a=10.2840(4)Å b=10.9921(3)Å c=17.9147(7)Å
α=90.00° β=90.00° γ=90.00°
1,1ï-bis(1,3-dioxane-2-yl)-ferrocene
C18H22FeO4
Dalton Transactions (2003) 15 3098
a=5.8860(10)Å b=27.628(6)Å c=9.673(2)Å
α=90.00° β=93.50(3)° γ=90.00°
1,1ï-bis(1,3-dithiane-2-yl)-ferrocene
C18H22FeS4
Dalton Transactions (2003) 15 3098
a=12.203(2)Å b=18.686(4)Å c=9.861(2)Å
α=90.00° β=125.43(3)° γ=90.00°
(OC-6-43)-Dichlorido(N,N-dimethyl-ethane-1,2-diamine)dihydro- xidoplatinum(IV)
C4H14Cl2N2O2Pt
Dalton transactions (Cambridge, England : 2003) (2011) 40, 32 8187-8192
a=23.064(5)Å b=23.064(5)Å c=7.5597(16)Å
α=90.00° β=90.00° γ=90.00°
(OC-6-43)-Dichlorido(N,N-dimethyl-ethane-1,2- diamine)hydroxido(4-methoxy-4-oxobutanoato)platinum(IV)
C9H20Cl2N2O5Pt
Dalton transactions (Cambridge, England : 2003) (2011) 40, 32 8187-8192
a=8.1295(3)Å b=8.3664(3)Å c=11.0750(4)Å
α=89.567(3)° β=79.707(2)° γ=84.467(2)°
Catena-(bis(mu!3$(4,4',4''-benzene-1,3,5-triyl-tribenzoato)- O,O',O'') -tris((1,4,8,11-tetra-azacyclotetradecane)-nickel(ii)) hexahydrate)
2n(C42H51N6Ni1.5O6),6n(H2O)
Dalton transactions (Cambridge, England : 2003) (2012) 41, 14 4118-4125
a=7.1953(15)Å b=20.339(3)Å c=29.599(5)Å
α=90.00° β=94.67(2)° γ=90.00°
Catena-(bis(mu!3$-(4,4,4''-benzene-1,3,5-triyl-tribenzoato)- O,O',O'')-tris((3-methyl-1,3,5,8,12-penta-azacyclotetradecane)- nickel(ii)) hexahydrate)
2n(C42H52.5N7.5Ni1.5O6),6n(H2O)
Dalton transactions (Cambridge, England : 2003) (2012) 41, 14 4118-4125
a=7.3051(3)Å b=20.3203(8)Å c=29.5008(18)Å
α=90.00° β=92.816(5)° γ=90.00°
Catena-(bis(mu!3$-Benzene-1,3,5-tricarboxylato-O,O,O'')- tris((3-methyl-1, 3,5,8,12-penta-azacyclotetradecane)-nickel(ii)) decahydrate)
C48H101.5N15Ni3O22.25
Dalton transactions (Cambridge, England : 2003) (2012) 41, 14 4118-4125
a=9.2825(7)Å b=27.248(2)Å c=16.1584(11)Å
α=90.00° β=98.808(4)° γ=90.00°
C19H23Cl2O6OsP,0.35(O)
C19H23Cl2O6OsP,0.35(O)
Dalton transactions (Cambridge, England : 2003) (2010) 39, 31 7345-7352
a=8.7180(4)Å b=14.8768(7)Å c=17.0012(8)Å
α=90.00° β=90.00° γ=90.00°
3-Aminopyridine-2-carbaldehyde-thiosemicarbazone-dichlorido- zinc(ii) monoethanol solvate
C7H9Cl2N5SZn,C2H6O
Dalton transactions (Cambridge, England : 2003) (2010) 39, 3 704-706
a=11.4639(7)Å b=10.2716(5)Å c=12.7509(7)Å
α=90.00° β=99.422(4)° γ=90.00°
Bis(ethane-1,2-diamine-1kappa$2!N,N',2kappa$2!N,N')bis(miu-1- methylcytosinato-ka N3,N4)diplatinum(ii) dinitrate hydrate
2(C14H28N10O2Pt2),4(NO3),HO,4(H2O),2(O)
Dalton transactions (Cambridge, England : 2003) (2010) 39, 15 3633-3643
a=25.8439(13)Å b=16.1026(11)Å c=18.3805(12)Å
α=90.00° β=132.070(6)° γ=90.00°
Chlorido(ethane-1,2-diamine)(1-methylcytosine)platinum(ii) nitrate acetone solvate
C7H15ClN5OPt,0.5(C6H12O2),NO3
Dalton transactions (Cambridge, England : 2003) (2010) 39, 15 3633-3643
a=7.5962(5)Å b=8.4624(5)Å c=13.6279(10)Å
α=76.987(4)° β=77.081(4)° γ=86.098(4)°
Aqua-1kappaO)bis(ethane-1,2-diamine- 1kappa$2!N,N',2kappa$2!N,N') (hydroxido-2kappaO)bis(miu-1- methylcytosinato-kappa$2!N3,N4) diplatinum(iii)(Pt-Pt) triperchlorate monohydrate
C14H31N10O4Pt2,3(ClO4),H2O
Dalton transactions (Cambridge, England : 2003) (2010) 39, 15 3633-3643
a=11.2503(4)Å b=12.3786(4)Å c=13.0732(5)Å
α=67.701(2)° β=70.504(2)° γ=64.629(2)°
(Ethane-1,2-diamine)bis(1- methylcytosine)platinum(ii)dinitrate dihydrate
C12H22N8O2Pt,2(NO3),2(O)
Dalton transactions (Cambridge, England : 2003) (2010) 39, 15 3633-3643
a=10.7582(10)Å b=14.5690(17)Å c=14.0733(15)Å
α=90.00° β=101.110(6)° γ=90.00°
Chlorido(N,N'-dimethylethane-1,2-diamine)(1-methylcytosine)platinum(II) nitrate monohydrate
C9H19ClN5OPt,0.12(O8),NO3
Dalton transactions (Cambridge, England : 2003) (2010) 39, 15 3633-3643
a=12.4934(4)Å b=12.7860(4)Å c=12.6634(4)Å
α=90.00° β=118.875(2)° γ=90.00°
Bis(ethane-1,2-diamine-1kappa$2!N,N',2kappa$2!N,N')bis(miu-1- methylcytosinato-kappa$2!N3,N4)(disulfato- 1kappaO,2kappaO)diplatinum(iii)(Pt-Pt) hydrate
C14H28N10O10Pt2S2,2(H2O),2(O0.80)
Dalton transactions (Cambridge, England : 2003) (2010) 39, 15 3633-3643
a=19.8579(6)Å b=12.0130(6)Å c=14.3117(6)Å
α=90.00° β=125.859(4)° γ=90.00°